10 Lymphoma Clinical Trials in Baltimore, MD (2026)

Q: How do I join a clinical trial in Baltimore?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Baltimore research site will contact you.

Recruiting Lymphoma Studies in Baltimore

NCT06091865Recruiting

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with Diffuse Large B-cell Ly...

Baltimore, MDPHASE3904 participantsRegeneron Pharmaceuticals

View Study Details

NCT04104776Recruiting

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid ...

Baltimore, MDPHASE1300 participantsNovartis Pharmaceuticals

View Study Details

NCT04989803Recruiting

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

The goal of this clinical study is to learn more about the safety and effectiveness of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma....

Baltimore, MDPHASE1247 participantsKite, A Gilead Company

View Study Details

NCT06116110Recruiting

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1....

Baltimore, MD150 participantsMiltenyi Biomedicine GmbH

View Study Details

NCT06561048Recruiting

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapse...

Baltimore, MDPHASE3150 participantsCorvus Pharmaceuticals, Inc.

View Study Details

NCT05365659Recruiting

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of I...

Baltimore, MDPHASE1140 participantsIksuda Therapeutics Ltd.

View Study Details

NCT03666000Recruiting

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T,...

Baltimore, MDPHASE1135 participantsImugene Limited

View Study Details

NCT05533775Recruiting

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

The purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and et...

Baltimore, MDPHASE165 participantsHoffmann-La Roche

View Study Details

NCT07003295Recruiting

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

This phase II trial tests the safety and side effects of glofitamab and obinutuzumab and how well they work in treating patients with mantle cell lymphoma that has come back after a period of improvem...

Baltimore, MDPHASE220 participantsNational Cancer Institute (NCI)

View Study Details

NCT04139304Recruiting

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

This feasibility trial studies how well daratumumab in combination with dose-adjusted etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (DA-EPOCH) works in tr...

Baltimore, MDEARLY_PHASE115 participantsAIDS Malignancy Consortium

View Study Details

About Lymphoma Clinical Trials in Baltimore

Lymphoma is a cancer of the lymphatic system that affects infection-fighting cells called lymphocytes. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma. Treatment often includes chemotherapy, radiation, immunotherapy, and in some cases stem cell transplant.

There are currently 10 lymphoma clinical trials recruiting participants in Baltimore, MD. These studies are seeking a combined 2,126 participants. Research is being sponsored by Regeneron Pharmaceuticals, Novartis Pharmaceuticals, Kite, A Gilead Company and 7 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lymphoma Clinical Trials in Baltimore — FAQ

Are there lymphoma clinical trials in Baltimore?

Yes, there are 10 lymphoma clinical trials currently recruiting in Baltimore, MD. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Baltimore?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Baltimore research site will contact you about next steps.

Are clinical trials in Baltimore free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Baltimore studies also compensate for your time and travel.

What lymphoma treatments are being tested?

The 10 active trials in Baltimore are testing new therapies including novel drugs, biologics, and treatment approaches for lymphoma.

Data updated July 18, 2026 from ClinicalTrials.gov